Modern Approaches to the Management of Patients with Urticaria

The Union of Pediatricians of Russia together with the Russian Association of Allergologists and Clinical Immunologists and the Russian Society of Dermatovenerologists and Cosmetologists have developed new clinical guidelines for the urticaria in adults and children. Urticaria is a common disease; its various clinical variants are diagnosed in 15–25% of people in the global population, and a quarter of all cases belongs to chronic urticaria. The prevalence of acute urticaria is 20%, and 2.1–6.7% in child population, whereas acute urticaria is more common in children than in adults. The prevalence of chronic urticaria in adults in the general population is 0.7 and 1.4%, and 1.1% in children under 15 years of age, according to the systematic review and meta-analysis, respectively. This article covers features of epidemiology, etiology, and pathogenesis of the disease with particular focus on differential diagnostic search. Guidelines on treatment and step-by-step therapy scheme (both based on principles of evidencebased medicine) for pediatric patients were presented. Clarification on the analysis of the therapy efficacy and the degree of disease activity was given.

1. Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu krapivnitsy. Moscow: Russian Association of Allergists and Clinical Immunologists; 2015. 34 p. (In Russ).

2. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–766. doi: https://doi.org/10.1111/all.15090

3. Bracken SJ, Abraham S, MacLeod AS. Autoimmune Theories of Chronic Spontaneous Urticaria. Front Immunol. 2019;10:627. doi: https://doi.org/10.3389/fimmu.2019.00627

4. Maurer M, Altrichter S, Schmetzer O, et al. Immunoglobulin E-Mediated Autoimmunity. Front Immunol. 2018;9:689. doi: https://doi.org/10.3389/fimmu.2018.00689

5. Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: What we know and what we do not know. J Allergy Clin Immunol. 2017;139(6):1772–1781.e1. doi: https://doi.org/10.1016/j.jaci.2016.08.050

6. Vonakis BM, Vasagar K, Gibbons SP Jr, et al. Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol. 2007;119(2):441–448. doi: https://doi.org/10.1016/j.jaci.2006.09.035

7. Luquin E, Kaplan AP, Ferrer M. Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-responsiveness to other stimuli. Clin Exp Allergy. 2005;35(4):456–460. doi: https://doi.org/10.1111/j.1365-2222.2005.02212.x

8. Gibbs BF, Räthling A, Zillikens D, et al. Initial Fc epsilon RI-mediated signal strength plays a key role in regulating basophil signaling and deactivation. J Allergy Clin Immunol. 2006;118(5):1060–1067. doi: https://doi.org/10.1016/j.jaci.2006.07.022

9. Maurer M, Church MK, Gonçalo M, et al. Management and treatment of chronic urticaria (CU). J Eur Acad Dermatol Venereol. 2015;29(3):16–32. doi: https://doi.org/10.1111/jdv.13198

10. Greenberger PA. Chronic urticaria: new management options. World Allergy Organ J. 2014;7(1):31. doi: https://doi.org/10.1186/1939-4551-7-31

11. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270–1277. doi: https://doi.org/10.1016/j.jaci.2014.02.036

12. Pite H, Wedi B, Borrego LM, et al. Management of childhood urticaria: current knowledge and practical recommendations. Acta Derm Venereol. 2013;93(5):500–508. doi: https://doi.org/10.2340/00015555-1573

13. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy. 2011;66(3):317–330. doi: https://doi.org/10.1111/j.1398-9995.2010.02496.x

14. Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy. 2020;75(2):423–432. doi: https://doi.org/10.1111/all.14037

15. Saini S, Shams M, Bernstein JA, Maurer M. Urticaria and angioedema across the ages. J Allergy Clin Immunol Pract. 2020;8(6):1866– 1874. doi: https://doi.org/10.1016/j.jaip.2020.03.0302-6

16. Goldstein S, Gabriel S, Kianifard F, et al. Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: review of omalizumab clinical trials. Ann Allergy Asthma Immunol. 2017;118(4):500– 504. doi: https://doi.org/10.1016/j.anai.2017.02.0035

17. Curto-Barredo L, Pujol RM, Roura-Vives G, Gimenez-Arnau AM. Chronic urticaria phenotypes: clinical differences regarding triggers, activity, prognosis and therapeutic response. Eur J Dermatol. 2019;29(6):627–635. doi: https://doi.org/10.1684/ejd.2019.3674

18. Netchiporouk E, Sasseville D, Moreau L, et al. Evaluating comorbidities, natural history, and predictors of early resolution in a cohort of children with chronic urticaria. JAMA Dermatol. 2017;153(12):1236–1242. doi: https://doi.org/10.1001/jamadermatol.2017.3182

19. Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med. 2002;346(3):175–179. doi: https://doi.org/10.1056/NEJMcp011186

20. Caffarelli C, Paravati F, El Hachem M, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr. 2019;45(1):101. doi: https://doi.org/10.1186/s13052-019-0695-x

21. Toubi E, Kessel A, Avshovich N, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy. 2004;59(8):869–873. doi: https://doi.org/10.1111/j.1398-9995.2004.00473.x

22. Schoepke N, Doumoulakis G, Maurer M. Diagnosis of urticaria. Indian J Dermatol. 2013;58(3):211–218. doi: https://doi.org/10.4103/0019-5154.110831

23. Allergiya u detei: ot teorii k praktike. Namazova- Baranova LS, ed. Moscow: Union of Pediatricians of Russia; 2010. 668 p. (In Russ).

24. Nettis E, Foti C, Ambrifi M, et al. Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology. Clin Mol Allergy. 2020;18:8. doi: https://doi.org/10.1186/s12948-020-00123-8

25. Metz M, Altrichter S, Buttgereit T, et al. The Diagnostic Workup in Chronic Spontaneous Urticaria-What to Test and Why. J Allergy Clin Immunol Pract. 2021;9(6):2274–2283. doi: https://doi.org/10.1016/j.jaip.2021.03.049

26. Kolkhir P, André F, Church MK, et al. Potential blood biomarkers in chronic spontaneous urticaria. Clin Exp Allergy. 2017;47(1):19– 36. doi: https://doi.org/10.1111/cea.12870

27. Altrichter S, Fok JS, Jiao Q, et al. Total IgE as a Marker for Chronic Spontaneous Urticaria. Allergy Asthma Immunol Res. 2021;13(2):206–218. doi: https://doi.org/10.4168/aair.2021.13.2.206

28. Fok JS, Kolkhir P, Church MK, Maurer M. Predictors of treatment response in chronic spontaneous urticaria. Allergy. 2021;76(10):2965–2981. doi: https://doi.org/10.1111/all.14757

29. Kolkhir P, Altrichter S, Asero R, et al. Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria. Allergy Asthma Immunol Res. 2021;13(4):545–559. doi: https://doi.org/10.4168/aair.2021.13.4.545

30. Cornillier H, Giraudeau B, Munck S, et al. Chronic spontaneous urticaria in children — a systematic review on interventions and comorbidities. Pediatr Allergy Immunol. 2018;29(3):303–310. doi: https://doi.org/10.1111/pai.12870

31. Spickett G. Urticaria and angioedema. J R Coll Physicians Edinb. 2014;44(1):50–54. doi: https://doi.org/10.4997/JRCPE.2014.112

32. Kolkhir P, Balakirski G, Merk HF, et al. Chronic spontaneous urticaria and internal parasites--a systematic review. Allergy. 2016;71(3):308–322. doi: https://doi.org/10.1111/all.12818

33. Minciullo PL, Cascio A, Gangemi S. Association between urticaria and nematode infections. Allergy Asthma Proc. 2018;39(2):86–95. doi: https://doi.org/10.2500/aap.2018.38.4104

34. Fedorova OS, Fedotova MM, Zvonareva OI, et al. Opisthorchis felineus infection, risks, and morbidity in rural Western Siberia, Russian Federation. PLoS Negl Trop Dis. 2020;14(6):e0008421. doi: https://doi.org/10.1371/journal.pntd.0008421

35. Sayasone S, Odermatt P, Phoumindr N, et al. Epidemiology of Opisthorchis viverrini in a rural district of southern Lao PDR. Trans R Soc Trop Med Hyg. 2007;101(1):40–47. doi: https://doi.org/10.1016/j.trstmh.2006.02.018

36. Neumayr A. Antiparasitic treatment recommendations: A practical guide to clinical parasitology. Hamburg: Tredition GmbH; 2016. 173 p.

37. Ataseven A, Durmaz K, Ozer I, Dursun R. Gallstones at chronic spontaneous urticaria patients: A retrospective clinical study. Dermatol Ther. 2020;33(2):e13212. doi: https://doi.org/10.1111/ dth.13212

38. Minciullo PL, Cascio A, Barberi G, Gangemi S. Urticaria and bacterial infections. Allergy Asthma Proc. 2014;35(4):295–302. doi: https://doi.org/10.2500/aap.2014.35.3764

39. Imbalzano E, Casciaro M, Quartuccio S, et al. Association between urticaria and virus infections: A systematic review. Allergy Asthma Proc. 2016;37(1):18–22. doi: https://doi.org/10.2500/ aap.2016.37.3915

40. Sugrañes-Montalván A, Barreto-Suárez E, Nicolau-Pestana E, Quesada-Leyva L. Relación entre infección por Helicobacter pylori y urticaria crónica. Rev Alerg Mex. 2017;64(4):396–402. doi: https://doi.org/10.29262/ram.v64i4.283

41. Kim HJ, Kim YJ, Lee HJ, et al. Systematic review and metaanalysis: Effect of Helicobacter pylori eradication on chronic spontaneous urticaria. Helicobacter. 2019;24(6):e12661. doi: https://doi.org/10.1111/hel.12661

42. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/ EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy. 2018;73(8):1575–1596. doi: https://doi.org/10.1111/all.13384

43. Caballero T, Baeza ML, Cabañas R, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. J Investig Allergol Clin Immunol. 2011;21(6):422–441; quiz 442–443.

44. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602–616. doi: https://doi.org/10.1111/all.12380

45. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6(1):24. doi: https://doi.org/10.1186/1710-1492-6-24

46. Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(3 Suppl):S51–S131. doi: https://doi.org/10.1016/j.jaci.2004.06.047

47. Peroni A, Colato C, Schena D, Girolomoni G. Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part 1. Cutaneous diseases. J Am Acad Dermatol. 2010;62:541–555. doi: https://doi.org/10.1016/j.jaad.2009.11.686

48. Niu XL, Zhu LL, Shi MH, et al. Association of positive and negative autologous serum skin test responses with clinical features of chronic spontaneous urticaria in Asian patients: A systematic review and meta-analysis. Exp Ther Med. 2019;17(4):2603–2613. doi: https://doi.org/10.3892/etm.2019.7266

49. Kulthanan K, Subchookul C, Hunnangkul S, et al. Factors Predicting the Response to Cyclosporin Treatment in Patients With Chronic Spontaneous Urticaria: A Systematic Review. Allergy Asthma Immunol Res. 2019;11(5):736–755. doi: https://doi.org/10.4168/aair.2019.11.5.736

50. George M, Balachandran C, Prabhu S. Chronic idiopathic urticaria: comparison of clinical features with positive autologous serum skin test. Indian J Dermatol Venereol Leprol. 2008;74(2):105–108. doi: https://doi.org/10.4103/0378-6323.39690

51. Khan DA. Chronic spontaneous urticaria: Standard management and patient education. In: UpToDate. Last updated: Apr 26, 2022. Available online: https://www.uptodate.com/contents/chronicspontaneous-urticaria-standard-management-and-patient-educatio n?search=urticaria&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2. Accessed on September 30, 2023.

52. Cicardi M, Bellis P, Bertazzoni G, et al. Guidance for diagnosis and treatment of acute angioedema in the emergency department: consensus statement by a panel of Italian experts. Intern Emerg Med. 2014;9(1):85–92. doi: https://doi.org/10.1007/s11739-013-0993-z

53. Depetri F, Tedeschi A, Cugno M. Angioedema and emergency medicine: From pathophysiology to diagnosis and treatment. Eur J Intern Med. 2019;59:8–13. doi: https://doi.org/10.1016/j. ejim.2018.09.004

54. Adeyeni TA, Domack A, Britt C. What Is the Role of Laryngoscopy in Angioedema Isolated to the Lips, Without Laryngeal Symptoms? Laryngoscope. 2020;130(12):2740–2741. doi: https://doi.org/10.1002/lary.28664

55. Weller K, Groffik A, Magerl M, et al. Development, validation, and initial results of the Angioedema Activity Score. Allergy. 2013;68(9):1185–1192. doi: https://doi.org/10.1111/all.12209

56. Shikiar R, Harding G, Leahy M, Lennox RD. Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria. Health Qual Life Outcomes. 2005;3:36. doi: https://doi.org/10.1186/1477-7525-3-36

57. Prosty C, Gabrielli S, Mule P, et al. Validation of the Urticaria Control Test (UCT) in Children With Chronic Urticaria. J Allergy Clin Immunol Pract. 2022;10(12):3293–3298.e2. doi: https://doi.org/10.1016/j.jaip.2022.07.037

58. Młynek A, Zalewska-Janowska A, Martus P, et al. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63(6):777–780. doi: https://doi.org/10.1111/j.1398- 9995.2008.01726.x

59. Patruno C, Napolitano M, Ferrucci S, et al. Four-week Urticaria Activity Score-7 as a Useful Patient-reported Outcome to Assess Chronic Spontaneous Urticaria: A Multicentre Study Evaluation of Adherence and Patients’ Perspective. Acta Derm Venereol. 2019;99(10):903–904. doi: https://doi.org/10.2340/00015555-3231

60. Borzova EYu, Salugina SО. Current Problems in the Differential Diagnosis of Urticaria. Effective Pharmacotherapy. Allergology and Immunology. 2017;7(1):34–44. (In Russ).

61. Soter NA. Chronic urticaria as a manifestation of necrotizing venulitis. N Engl J Med. 1977;296(25):1440–1442. doi: https://doi.org/10.1056/NEJM197706232962505

62. Danilycheva IV, Borzova EYu, Il’ina NI. Urtikarnyi vaskulit. Ot diagnostiki k lecheniyu. Russian Journal of Allergy. 2012;5(1):71–76. (In Russ).

63. Brodell LA, Beck LA. Differential diagnosis of chronic urticaria. Ann Allergy Asthma Immunol. 2008;100(3):181–215. doi: https://doi.org/10.1016/S1081-1206(10)60438-3

64. Makhneva NV. Sovremennyi vzglyad na diagnostiku i lechenie bulleznykh dermatozov. International Journal of Applied and Fundamental Research. 2011;(9):15–17. (In Russ).

65. Banchenko GV, Fleisher GM, Gorin AA. Opyt lecheniya mnogoformnoi ekssudativnoi eritemy. Medical alphabet. 2013;1(1):44–46. (In Russ).

66. Patel S, Patel R, Draikiwicz S, Capitle E. Peripheral T-cell lymphoma: a challenging mimicker of angioedema and urticaria. Ann Allergy Asthma Immunol. 2015;115(2):94–95. doi: https://doi.org/10.1016/j.anai.2015.06.013

67. Brockow K. Urticaria pigmentosa. Immunol Allergy Clin North Am. 2004;24(2):287-vii. doi: https://doi.org/10.1016/j.iac.2004.01.002

68. Khaliulin YuG. Mastocitosis: clinical manifestations, the methods of diagnostics and the tactics of observation the patients. Lechaschi Vrach. 2012;(8):83–89. (In Russ).

69. Mukhin N, Moiseev C, Popova E, et al. Pozdnie proyavleniya Laimskoi bolezni. Vrach (The Doctor). 2006;(5):35–38. (In Russ).

70. Kochergin N, Nikitina E, Tsykin A. Nekotorye osobennosti dermatozov beremennykh. Vrach (The Doctor). 2010;(1):51–55. (In Russ).

71. Novikov DK, Sergeev YuV, Novikov PD, Sergeev AYu. Adverse allergic reactions on drugs and other preparations in dermathology. Immunopathology, Allergology, Infectology. 2003;(3):45– 67. (In Russ). doi: https://doi.org/10.14427/jipai.2018.3.60

72. Foer D, Buchheit KM, Gargiulo AR, et al. Progestogen Hypersensitivity in 24 Cases: Diagnosis, Management, and Proposed Renaming and Classification. J Allergy Clin Immunol Pract. 2016;4(4):723–729. doi: https://doi.org/10.1016/j.jaip.2016.03.003

73. Antonova OV, Trofimov PN, Belousova IE, Samtsov AV. Reticular erythematous mucinosis. Vestnik Dermatologii i Venerologii. 2014;(5):96–99. (In Russ).

74. Kolkhir P, Pogorelov D, Olisova O, Maurer M. Comorbidity and pathogenic links of chronic spontaneous urticaria and systemic lupus erythematosus — a systematic review. Clin Exp Allergy. 2016;46(2):275–287. doi: https://doi.org/10.1111/cea.12673

75. Kuz’mina NN, Salugina CO, Fedorov EC. Autovospalitel’nye zabolevaniya i sindromy u detei: Educational and methodological manual. Moscow: IMAPRESS; 2012. (In Russ).

76. Barron K, Athreya B, Kastner D. Periodic fever syndromes and other inherited autoinflammatory diseases. In: Textbook of pediatric rheumatology. Cassidy JT, Petty RE, eds. 7th ed. Elsevier Saunders; 2015. pp. 609–641.

77. Toplak N, Frenkel J, Ozen S, et al. An international registry on autoinflammatory diseases: the Eurofever experience. Ann Rheum Dis. 2012;71(7):1177–1182. doi: https://doi.org/10.1136/annrheumdis-2011-200549

78. Simon A, Asli B, Braun-Falco M, et al. Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy. 2013;68(5):562–568. doi: https://doi.org/10.1111/all.12129

79. De Castro FR, Masouye I, Winkelmann RK, Saurat JH. Urticarial pathology in Schnitzler’s (hyper-IgM) syndrome. Dermatology. 1996;193(2):94–99.

80. Znamenskaya LF, Osokina DE, Vavilov AM. Sweet-Syndrome. Vestnik dermatologii i venerologii. 2008;(2):94– 96. (In Russ).

81. Butterfield JH. Flushing and urticarial syndromes presenting as anaphylaxis. In: Anaphylaxis and hypersensitivity reactions. Castells M, ed. Springer; 2010. pp. 271–284.

82. Kheger PG. Detskaya dermatologiya: differentsial’naya diagnostika i lechenie u detei i podrostkov. Moscow: Izdatel’stvo Panfilova; 2013. 634 p. (In Russ).

83. Allergologiya i immunologiya: Practical recommendations for pediatricians. Namazova-Baranova LS, Baranov AA, Khaitov RM, eds. Moscow: Pediatr; 2020. 512 p. (In Russ).

84. Hocqueloux L, Guinard J, Buret J, et al. Do penicillins really increase the frequency of a rash when given during Epstein-Barr Virus primary infection? Clin Infect Dis. 2013;57(11):1661–1662. doi: https://doi.org/10.1093/cid/cit553

85. Dibek Misirlioglu E, Guvenir H, Ozkaya Parlakay A, et al. Incidence of Antibiotic-Related Rash in Children with Epstein-Barr Virus Infection and Evaluation of the Frequency of Confirmed Antibiotic Hypersensitivity. Int Arch Allergy Immunol. 2018;176(1):33–38. doi: https://doi.org/10.1159/000481988

86. Kowalski ML, Woessner K, Sanak M. Approaches to the diagnosis and management of patients with a history of nonsteroidal antiinflammatory drug-related urticaria and angioedema. J Allergy Clin Immunol. 2015;136(2):245–251. doi: https://doi.org/10.1016/j. jaci.2015.06.021

87. Shakouri A, Compalati E, Lang DM, Khan DA. Effectiveness of Helicobacter pylori eradication in chronic urticaria: evidence-based analysis using the Grading of Recommendations Assessment, Development, and Evaluation system. Curr Opin Allergy Clin Immunol. 2010;10(4):362– 369. doi: https://doi.org/10.1097/ACI.0b013e32833c79d7

88. Ishaq S, Nunn L. Helicobacter pylori and gastric cancer: a state of the art review. Gastroenerol Hepatol Bed Bench. 2015;8(Suppl 1):S6–S14.

89. Arik Yilmaz E, Karaatmaca B, Sackesen C, et al. Parasitic Infections in Children with Chronic Spontaneous Urticaria. Int Arch Allergy Immunol. 2016;171(2):130–135. doi: https://doi.org/10.1159/000450953

90. Zuberbier T, Chantraine Kess S, Hartmann K, Czarnetzki BM. Pseudoallergen-free diet in the treatment of chronic urticaria — a prospective study. Acta Derm Venereol. 1995;75(6):484–487. doi: https://doi.org/10.2340/0001555575484487

91. Cornillier H, Giraudeau B, Samimi M, et al. Effect of Diet in Chronic Spontaneous Urticaria: A Systematic Review. Acta Derm Venereol. 2019;99(2):127–132. doi: https://doi.org/10.2340/00015555-3015

92. Nettis E, Colanardi MC, Ferrannini A, Tursi A. Sodium benzoateinduced repeated episodes of acute urticaria/angio-oedema: randomized controlled trial. Br J Dermatol. 2004;151(4):898–902. doi: https://doi.org/10.1111/j.1365-2133.2004.06095.x

93. Akoglu G, Atakan N, Cakır B, et al. Effects of low pseudoallergen diet on urticarial activity and leukotriene levels in chronic urticaria. Arch Dermatol Res. 2012;304(4):257–262. doi: https:// doi.org/10.1007/s00403-011-1203-3

94. Son JH, Chung BY, Kim HO, Park CW. A Histamine-Free Diet Is Helpful for Treatment of Adult Patients with Chronic Spontaneous Urticaria. Ann Dermatol. 2018;30(2):164–172. doi: https://doi.org/10.5021/ad.2018.30.2.164

95. Sánchez-Pérez S, Comas-Basté O, Veciana-Nogués MT, et al. Low-Histamine Diets: Is the Exclusion of Foods Justified by Their Histamine Content? Nutrients. 2021;13(5):1395. doi: https://doi.org/10.3390/nu13051395

96. Allergologiya: Federal clinical guidelines. Khaitov RM, Il’ina NI. Moscow: Farmarus Print media; 2014. 126 p. (In Russ).

97. Beissert S, Ständer H, Schwarz T. UVA rush hardening for the treatment of solar urticaria. J Am Acad Dermatol. 2000;42(6):1030– 1032. doi: https://doi.org/10.1016/s0190-9622(00)90299-8

98. Kring Tannert L, Stahl Skov P, Bjerremann Jensen L, et al. Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction. Dermatology. 2012;224(2):101–105. doi: https://doi.org/10.1159/000336572

99. Sharma M, Bennett C, Cohen SN, Carter B. H1-antihistamines for chronic spontaneous urticaria. Cochrane Database Syst Rev. 2014;2014(11):CD006137. doi: https://doi.org/10.1002/14651858.CD006137

100. Williams PV. Pharmacologic Management of Chronic Urticaria in Pediatric Patients: The Gap Between Guidelines and Practice. Paediatr Drugs. 2020;22(1):21–28. doi: https://doi.org/10.1007/s40272-019-00365-3

101. Kudryavtseva AV, Neskorodova KA, Staubach P. Urticaria in children and adolescents: An updated review of the pathogenesis and management. Pediatr Allergy Immunol. 2019;30(1):17–24. doi: https://doi.org/10.1111/pai.12967

102. Nakamura T, Hiraoka K, Harada R, et al. Brain histamine H1 receptor occupancy after oral administration of desloratadine and loratadine. Pharmacol Res Perspect. 2019;7(4):e00499. doi: https://doi.org/10.1002/prp2.499

103. Haria M, Fitton A, Peters DH. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs. 1994;48(4):617–637. doi: https://doi.org/10.2165/00003495-199448040-00009

104. Zuraw B. An overview of angioedema: Clinical features, diagnosis, and management. In: UpToDate. Last updated: Sep 17, 2023. Available online: https://www.uptodate.com/contents/an-overview- of-angioedema-clinical-features-diagnosis-and-management? search=urticaria&topicRef=8108&source=related_link. Accessed on October 01, 2023.

105. Anafilakticheskii shok: Federal clinical guidelines. Russian Association of Allergists and Clinical Immunologists; Federation of Anesthesiologists and Reanimatologists. Moscow; 2022. (In Russ).

106. Zuberbier T, Iffländer J, Semmler C, Henz BM. Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol. 1996;76(4):295–297. doi: https://doi.org/10.2340/0001555576295297

107. Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol. 2010;20(5):386–390.

108. Talarico V, Marseglia GL, Lanari M, et al. Pediatric urticaria in the Emergency Department: epidemiological characteristics and predictive factors for its persistence in children. Eur Ann Allergy Clin Immunol. 2021;53(2):80–85. doi: https://doi.org/10.23822/EurAnnACI.1764-1489.148

109. Long BJ, Koyfman A, Gottlieb M. Evaluation and Management of Angioedema in the Emergency Department. West J Emerg Med. 2019;20(4):587–600. doi: https://doi.org/10.5811/westjem.2019.5.42650

110. Agache I, Rocha C, Pereira A, et al. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. Allergy. 2021;76(1):59–70. doi: https://doi.org/10.1111/all.14547

111. Aleksandraviciute L, Malinauskiene L, Cerniauskas K, Chomiciene A. Plasmapheresis: Is it a potential alternative treatment for chronic urticaria? Open Med (Wars). 2021;17(1):113–118. doi: https://doi.org/10.1515/med-2021-0399

112. Altrichter S, Salow J, Ardelean E, et al. Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria. J Dermatol Sci. 2014;75(2):88–93. doi: https://doi.org/10.1016/j.jdermsci.2014.04.007

113. Lee EE, Maibach HI. Treatment of urticaria. An evidence-based evaluation of antihistamines. Am J Clin Dermatol. 2001;2(1):27–32. doi: https://doi.org/10.2165/00128071-200102010-00005

114. Grob JJ, Auquier P, Dreyfus I, Ortonne JP. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy. 2009;64(4):605–612. doi: https:// doi.org/10.1111/j.1398-9995.2008.01913.x

115. Weller K, Ardelean E, Scholz E, et al. Can On-demand Nonsedating Antihistamines Improve Urticaria Symptoms? A Doubleblind, Randomized, Single-dose Study. Acta Derm Venereol. 2013;93(2):168–174. doi: https://doi.org/10.2340/00015555-1434

116. Murota H, Kitaba S, Tani M, et al. Impact of sedative and non-sedative antihistamines on the impaired productivity and quality of life in patients with pruritic skin diseases. Allergol Int. 2010;59(4):345–354. doi: https://doi.org/10.2332/allergolint.10-OA-0182

117. Fein MN, Fischer DA, O’Keefe AW, Sussman GL. CSACI position statement: newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy Asthma Clin Immunol. 2019;15:61. doi: https://doi.org/10.1186/s13223-019-0375-9

118. Chu DK, Oykhman P, Sussman GL. How to use antihistamines. CMAJ. 2021;193(14):E478–E479. doi: https://doi.org/10.1503/cmaj.201959

119. Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125(3):676–682. doi: https://doi.org/10.1016/j.jaci.2009.11.047

120. Siebenhaar F, Degener F, Zuberbier T, et al. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol. 2009;123(3):672–679. doi: https://doi.org/10.1016/j.jaci.2008.12.008

121. Giménez-Arnau A, Izquierdo I, Maurer M. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo-controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol. 2009;23(9):1088–1091. doi: https://doi.org/10.1111/j.1468-3083.2009.03289.x

122. Phinyo P, Koompawichit P, Nochaiwong S, et al. Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta- Analysis. J Allergy Clin Immunol Pract. 2021;9(2):956–970.e57. doi: https://doi.org/10.1016/j.jaip.2020.08.055

123. Iriarte Sotés P, Armisén M, Usero-Bárcena T, et al. Efficacy and Safety of Up-dosing Antihistamines in Chronic Spontaneous Urticaria: A Systematic Review of the Literature. J Investig Allergol Clin Immunol. 2021;31(4):282–291. doi: https://doi.org/10.18176/jiaci.0649

124. Guillén-Aguinaga S, Jáuregui Presa I, Aguinaga-Ontoso E, et al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol. 2016;175(6):1153–1165. doi: https://doi.org/10.1111/ bjd.14768

125. Church MK, Tiongco-Recto M, Ridolo E, Novák Z. Bilastine: a lifetime companion for the treatment of allergies. Curr Med Res Opin. 2020;36(3):445–454. doi: https://doi.org/10.1080/03007 995.2019.1681134

126. Kontou-Fili K, Maniatakou G, Demaka P, et al. Therapeutic effects of cetirizine in delayed pressure urticaria: clinicopathologic findings. J Am Acad Dermatol. 1991;24(6 Pt 2):1090–1093. doi: https://doi.org/10.1016/0190-9622(91)70163-v

127. Zuberbier T, Münzberger C, Haustein U, et al. Doubleblind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology. 1996;193(4):324–327. doi: https://doi.org/10.1159/000246281

128. Zhang L, Wu J, Qi Y, et al. Long-term combinations and updosing of second-generation H1-antihistamines show efficacy and safety in the treatment of chronic spontaneous urticaria: A multicenter reallife pilot study. J Allergy Clin Immunol Pract. 2020;8(5):1733–1736. e11. doi: https://doi.org/10.1016/j.jaip.2019.12.006

129. Sarti L, Barni S, Giovannini M, et al. Efficacy and tolerability of the updosing of second-generation non-sedating H1 antihistamines in children with chronic spontaneous urticaria. Pediatr Allergy Immunol. 2021;32(1):153–160. doi: https://doi.org/10.1111/pai.13325

130. Koosakulchai V, Yuenyongviwat A, Sangsupawanich P. Risk factors of uncontrolled symptoms using the standard dose of secondgeneration H1-antihistamines in chronic spontaneous urticaria children. Asian Pac J Allergy Immunol. 2022;40(2):121–125. doi: https://doi.org/10.12932/AP-030619-0573

131. Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742–1750.e4. doi: https://doi.org/10.1016/j.jaci.2015.12.1342

132. Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638–649. doi: https://doi.org/10.1016/j.jaci.2017.06.032

133. Tharp MD, Bernstein JA, Kavati A, et al. Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of “Real-world” Evidence. JAMA Dermatol. 2019;155(1):29–38. doi: https://doi.org/10.1001/jamadermatol.2018.3447

134. Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128(3):567–573.e1. doi: https://doi.org/10.1016/j.jaci.2011.06.010

135. Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128(1):202–209.e5. doi: https://doi.org/10.1016/j.jaci.2011.04.038

136. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67– 75. doi: https://doi.org/10.1038/jid.2014.306

137. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924–935. doi: https://doi.org/10.1056/ NEJMoa1215372

138. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101–109. doi: 10.1016/j.jaci.2013.05.013

139. Urgert MC, van den Elzen MT, Knulst AC, et al. Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment. Br J Dermatol. 2015;173(2):404–415. doi: https://doi.org/10.1111/bjd.13845

140. Rubini NPM, Ensina LFC, Silva EMK, et al. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis. Allergol Immunopathol (Madr). 2019;47(6):515–522. doi: https://doi.org/10.1016/j.aller.2019.05.003

141. Jia HX, He YL. Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Ther. 2020;27(5):e455–e467. doi: https://doi.org/10.1097/MJT.0000000000000912

142. Summary of Product Characteristics — Xolair (omalizumab). Available online: https://www.ema.europa.eu/en/documents/product-information/xolair-epar-product-information_en.pdf. Accessed on October 01, 2023.

143. Kocatürk E, Deza G, Kızıltaç K, Giménez-Arnau AM. Omalizumab Updosing for Better Disease Control in Chronic Spontaneous Urticaria Patients. Int Arch Allergy Immunol. 2018;177(4):360–364. doi: https://doi.org/10.1159/000491530

144. Metz M, Vadasz Z, Kocatürk E, Giménez-Arnau AM. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real- World Evidence. Clin Rev Allergy Immunol. 2020;59(1):38–45. doi: https://doi.org/10.1007/s12016-020-08794-6

145. Manzoor H, Razi F, Rasheed A, et al. Efficacy of Different Dosing Regimens of IgE Targeted Biologic Omalizumab for Chronic Spontaneous Urticaria in Adult and Pediatric Populations: A Meta- Analysis. Healthcare (Basel). 2022;10(12):2579. doi: https://doi.org/10.3390/healthcare10122579

146. Staubach P, Peveling-Oberhag A, Lang BM, et al. Severe chronic spontaneous urticaria in children — treatment options according to the guidelines and beyond — a 10 years review. J Dermatolog Treat. 2022;33(2):1119–1122. doi: https://doi.org/10.1080/09546634.2020.1782326

147. Stellato C, de Paulis A, Ciccarelli A, et al. Anti-inflammatory effect of cyclosporin A on human skin mast cells. J Invest Dermatol. 1992;98(5):800–804. doi: https://doi.org/10.1111/1523-1747.ep12499960

148. Harrison CA, Bastan R, Peirce MJ, et al. Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. Br J Pharmacol. 2007;150(4):509–518. doi: https://doi.org/10.1038/sj.bjp.0707002

149. Boubouka CD, Charissi C, Kouimintzis D, et al. Treatment of autoimmune urticaria with low-dose cyclosporin A: A one-year follow-up. Acta Derm Venereol. 2011;91(1):50–54. doi: https://doi.org/10.2340/00015555-0939

150. Grattan CE, O’Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br J Dermatol. 2000;143(2):365–372. doi: https://doi.org/10.1046/j.1365-2133.2000.03664.x

151. Vena GA, Cassano N, Colombo D, et al. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2006;55(4):705–709. doi: https://doi.org/10.1016/j.jaad.2006.04.078

152. Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review. J Allergy Clin Immunol Pract. 2018;6(2):586–599. doi: https://doi.org/10.1016/j.jaip.2017.07.017

153. Doshi DR, Weinberger MM. Experience with cyclosporine in children with chronic idiopathic urticaria. Pediatr Dermatol. 2009;26(4):409–413. doi: https://doi.org/10.1111/j.1525-1470.2009.00869.x

154. Sánchez J, Alvarez L, Cardona R. Cyclosporine and omalizumab together: A new option for chronic refractory urticaria. J Allergy Clin Immunol Pract. 2020;8(6):2101–2103. doi: https://doi.org/10.1016/j.jaip.2020.02.012

155. Rosenblum JD, Nassau S, Fonacier L, Mawhirt SL. Concomitant treatment with omalizumab and cyclosporine for chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2020;125(1):111–112. doi: https://doi.org/10.1016/j.anai.2020.04.020

156. Mitchell S, Balp MM, Samuel M, et al. Systematic review of treatments for chronic spontaneous urticaria with inadequate response to licensed first-line treatments. Int J Dermatol. 2015;54(9):1088– 1104. doi: https://doi.org/10.1111/ijd.12727

157. Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol. 2010;63(6):949–974. doi: https://doi.org/10.1016/j.jaad.2010.02.062

158. Vena GA, Cassano N, D’Argento V, Milani M. Clobetasol propionate 0.05% in a novel foam formulation is safe and effective in the short-term treatment of patients with delayed pressure urticaria: a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2006;154(2):353–356. doi: https://doi.org/10.1111/j.1365-2133.2005.06986.x

159. Kozel MMA, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs. 2004;64(22):2515–2536. doi: https://doi.org/10.2165/00003495-200464220-00003

160. Barlow RJ, Macdonald DM, Black AK, Greaves MW. The effects of topical corticosteroids on delayed pressure urticaria. Arch Dermatol Res. 1995;287(3-4):285–288. doi: https://doi.org/10.1007/BF01105080

161. Holm JG, Ivyanskiy I, Thomsen SF. Use of nonbiologic treatments in antihistamine-refractory chronic urticaria: a review of published evidence. J Dermatolog Treat. 2018;29(1):80–97. doi: https://doi.org/10.1080/09546634.2017.1329505

162. Morgan M, Cooke A, Rogers L, et al. Double-blind placebocontrolled trial of dapsone in antihistamine refractory chronic idiopathic urticaria. J Allergy Clin Immunol Pract. 2014;2(5):601–606. doi: https://doi.org/10.1016/j.jaip.2014.06.004

163. Alkeraye S, AlRuhaimi DK. The Addition of Montelukast for the Treatment of Chronic Idiopathic Urticaria. Cureus. 2021;13(7):e16137. doi: https://doi.org/10.7759/cureus.16137

164. Akenroye AT, McEwan C, Saini SS. Montelukast reduces symptom severity and frequency in patients with angioedemapredominant chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2018;6(4):1403–1405. doi: https://doi.org/10.1016/j.jaip.2018.04.026

165. Grattan CE, Francis DM, Slater NG, et al. Plasmapheresis for severe, unremitting, chronic urticaria. Lancet. 1992;339(8801):1078– 1080. doi: https://doi.org/10.1016/0140-6736(92)90666-q

166. Etwel F, Faught LH, Rieder MJ, Koren G. The Risk of Adverse Pregnancy Outcome After First Trimester Exposure to H1 Antihistamines: A Systematic Review and Meta-Analysis. Drug Saf. 2017;40(2):121–132. doi: https://doi.org/10.1007/s40264-016-0479-9

167. Gonzalez-Estrada A, Geraci SA. Allergy Medications During Pregnancy. Am J Med Sci. 2016;352(3):326–331. doi: https://doi.org/10.1016/j.amjms.2016.05.030

168. Weber-Schoendorfer C, Schaefer C. The safety of cetirizine during pregnancy. A prospective observational cohort study. Reprod Toxicol. 2008;26(1):19–23. doi: https://doi.org/10.1016/j.reprotox.2008.05.053

169. Østensen M, Lockshin M, Doria A, et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford). 2008;47 Suppl 3:iii28–iii31. doi: https://doi.org/10.1093/rheumatology/ken168

170. Golembesky A, Cooney M, Boev R, et al. Safety of cetirizine in pregnancy. J Obstet Gynaecol. 2018;38(7):940–945. doi: https://doi.org/10.1080/01443615.2018.1441271

171. Schwarz EB, Moretti ME, Nayak S, Koren G. Risk of hypospadias in offspring of women using loratadine during pregnancy: a systematic review and meta-analysis. Drug Saf. 2008;31(9):775–788. doi: https://doi.org/10.2165/00002018-200831090-00006

172. Namazy J, Cabana MD, Scheuerle AE, et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015;135(2):407–412. doi: https://doi.org/10.1016/j.jaci.2014.08.025

173. González-Medina M, Curto-Barredo L, Labrador-Horrillo M, Giménez-Arnau A. Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases. J Eur Acad Dermatol Venereol. 2017;31(5):e245–e246. doi: https://doi.org/10.1111/jdv.14034

174. Ghazanfar MN, Thomsen SF. Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies. Case Rep Med. 2015;2015:368053. doi: https://doi.org/10.1155/2015/368053

175. Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol. 2020;145(2):528–536.e1. doi: https://doi.org/10.1016/j.jaci.2019.05.019

176. Ramsey-Goldman R, Schilling E. Immunosuppressive drug use during pregnancy. Rheum Dis Clin North Am. 1997;23(1):149–167. doi: https://doi.org/10.1016/s0889-857x(05)70320-3

177. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001;71(8):1051–1055. doi: https://doi.org/10.1097/00007890-200104270-00006

178. Paziana K, Del Monaco M, Cardonick E, et al. Ciclosporin use during pregnancy. Drug Saf. 2013;36(5):279–294. doi: https://doi.org/10.1007/s40264-013-0034-x

179. Sánchez-Borges M, Ansotegui IJ, Baiardini I, et al. The challenges of chronic urticaria part 2: Pharmacological treatment, chronic inducible urticaria, urticaria in special situations. World Allergy Organ J. 2021;14(6):100546. doi: https://doi.org/10.1016/j.waojou.2021.100546

180. Hacard F, Martin C, Verdu V, et al. Therapeutic patient education improves knowledge and skills for patients with chronic spontaneous urticaria. Eur J Dermatol. 2018;28(6):823–827. doi: https://doi.org/10.1684/ejd.2018.3442

181. Friedman AJ, Cosby R, Boyko S, et al. Effective teaching strategies and methods of delivery for patient education: a systematic review and practice guideline recommendations. J Cancer Educ. 2011;26(1):12– 21. doi: https://doi.org/10.1007/s13187-010-0183-x

182. Rooney MK, Santiago G, Perni S, et al. Readability of Patient Education Materials From High-Impact Medical Journals: A 20-Year Analysis. J Patient Exp. 2021;8:2374373521998847. doi: https://doi.org/10.1177/2374373521998847

183. Konstantinou GN, Konstantinou GN. Psychiatric comorbidity in chronic urticaria patients: a systematic review and meta-analysis. Clin Transl Allergy. 2019;9:42. doi: https://doi.org/10.1186/s13601-019-0278-3

184. Meditsinskie protivopokazaniya k provedeniyu profilakticheskikh privivok preparatami natsional’nogo kalendarya privivok: Guidelines. Moscow: Federal Center for State Sanitary and Epidemiological Surveillance of the Ministry of Health of Russia; 2002. 16 p. (In Russ).

185. Nebiolo F, Bergia R, Bommarito L, et al. Effect of arterial hypertension on chronic urticaria duration. Ann Allergy Asthma Immunol. 2009;103(5):407–410. doi: https://doi.org/10.1016/S1081-1206(10)60360-2

186. Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S. Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol. 2007;34(5):294–301. doi: https://doi.org/10.1111/j.1346-8138.2007.00276.x

187. Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol. 2001;45(3):387–391. doi: https://doi.org/10.1067/mjd.2001.116217

188. Hiragun M, Hiragun T, Mihara S, et al. Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine. Allergy. 2013;68(2):229–235. doi: https://doi.org/10.1111/all.12078

189. Cortellazzo Wiel L, Conversano E, Giangreco M, et al. Natural history and predictors of recovery in children with chronic spontaneous urticaria. Pediatr Allergy Immunol. 2021;32(1):201–204. doi: https://doi.org/10.1111/pai.13299

190. Özyılmaz-Bozat G, Şahiner ÜM, Buyuktiryaki B, et al. Children with chronic spontaneous urticaria: Recurrence after remission and its predictors. J Allergy Clin Immunol Pract. 2020;8(2):796–798.e1. doi: https://doi.org/10.1016/j.jaip.2019.08.010

191. Van der Valk PG, Moret G, Kiemeney LA. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol. 2002;146(1):110–113. doi: https://doi.org/10.1046/j.1365-2133.2002.04582.x